µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y420 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±Û·çÄÚÄÝƼÄÚÀÌµå ¹× ÇÕ¼º´ëÄ¡¹° Glucocorticoids and synthetic analogues causing adverse effects in therapeutic use
Y421 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °©»ó¼± È£¸£¸ó ¹× ´ëÄ¡¹° Thyroid hormones and substitutes causing adverse effects in therapeutic use
Y422 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°©»ó¼±Á¦ Antithyroid drugs causing adverse effects in therapeutic use
Y423 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Àν¶¸° ¹× °æ±¸ÀúÇ÷´ç[Ç×´ç´¢º´]Á¦ Insulin and oral hypoglycemic [antidiabetic] drugs causing adverse effects in therapeutic use
Y424 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °æ±¸ÇÇÀÓÁ¦ Oral contraceptives causing adverse effects in therapeutic use
Y424 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Ù¼ººÐ ¹× ´ÜÀϼººÐ Á¦Á¦ Multiple-and single-ingredient preparations causing adverse effects in therapeutic use
Y425 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð Other estrogens and progestogens causing adverse effects in therapeutic use
Y425 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È¥ÇÕ¹° ¹× ´ëÄ¡¹° Mixtures and substitutes causing adverse effects in therapeutic use
Y426 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×°í³ªµµÆ®·ÎÇÉÁ¦, Ç׿¡½ºÆ®·ÎÁ¨Á¦, Ç׾ȵå·ÎÁ¨Á¦ Antigonadotrophins, antiestrogens, antiandrogens, NEC causing adverse effects in therapeutic use
Y426 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ÿ¸ñ½ÃÆæ Tamoxifen causing adverse effects in therapeutic use
Y427 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Èµå·ÎÁ¨ ¹× ÇÕ¼º´ë»ç µ¿Á¾Ã¼ Androgens and anabolic congeners causing adverse effects in therapeutic use
Y428 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ¹× ÇÕ¼º ´ëÄ¡¹° Other and unspecified hormones and their synthetic substitutes causing adverse effects in therapeutic use
Y428 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³úÇϼöü Àü¿± È£¸£¸ó Anterior pituitary [adenohypophyseal] hormons causing adverse effects in therapeutic use
Y429 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ±æÇ×Á¦ Other and unspecified hormone antagonists causing adverse effects in therapeutic use
Y43 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ Primarily systemic agents causing adverse effects in therapeutic use
Y430 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾˷¹¸£±â ¹× Ç×±¸ÅäÁ¦ Antiallergic and antiemetic drugs causing adverse effects in therapeutic use
Y431 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº ´ë»ç¾ïÁ¦Á¦ Antineoplastic antimetabolites causing adverse effects in therapeutic use
Y431 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »çÀÌŸ¶óºó Cytarabine causing adverse effects in therapeutic use
Y432 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº õ¿¬¹° Antineoplastic natural products causing adverse effects in therapeutic use
Y433 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×¾ÏÁ¦ Other antineoplastic drugs causing adverse effects in therapeutic use
3871  3872  3873  3874  [3875] 3876  3877  3878  3879  3880